These findings strengthen the notion that an inflammatory axis approach, simultaneously evaluating both the biochemical (CRP) and cellular (DNI) faces of the myocardial remodeling process, may provide a more realistic assessment of disease burden in DCM. This evidence concerns the gene CRP and familial dilated cardiomyopathy.